Market Overview

Embolx Earns CE Mark Certification for Sniper Balloon Occlusion Microcatheters for Pressure-Directed Treatment of Tumors, Enlarged Prostate, Fibroids

Share:

Next-Generation Balloon Microcatheters Now Commercially Available
in Europe

Embolx,
Inc
., a medical device company developing microcatheters for
arterial embolization procedures, today announced CE Certifications for
its next-generation family of Sniper® Balloon Occlusion Microcatheters
for the treatment of cancerous tumors, enlarged prostate and uterine
fibroids. The novel system of microcatheters, which deliver
pressure-directed arterial embolization therapy, is now commercially
available in both the United States and Europe.

This press release features multimedia. View the full release here:
https://www.businesswire.com/news/home/20180831005444/en/

Sniper Balloon Occlusion Microcatheter (Photo: Embolx)

Sniper Balloon Occlusion Microcatheter (Photo: Embolx)

Sniper microcatheters increase therapeutic agent delivery to target
areas, while protecting surrounding healthy tissues, by controlling
pressure to alter blood flow. Embolx's next-generation Sniper
microcatheters are available in 110 cm, 130 cm and 150 cm lengths,
enabling interventional radiologist physicians to access through femoral
or radial arterial sites. Advancements in the Sniper balloon and
atraumatic tip designs also allow larger vessels to be occluded and
enhance the ability for Sniper to track inside vessels.

"CE Marking is an important milestone for Embolx, as we can now offer
the most advanced transarterial embolization delivery system to
physicians and patients in Europe," said Michael Allen, president and
CEO of Embolx. "For patients, the system's ability to redirect blood
flow away from surrounding organs and eliminate reflux may result in
better outcomes and fewer side effects."

Tiago Bilhim, MD, interventional radiologist at Hospital Saint Louis,
Lisbon, Portugal, commented, "We've used Sniper in approximately 50
prostate arterial embolizations so far this year, and we've seen
improved outcomes with fewer adverse events when compared to
conventional microcatheter embolization. Because Sniper prevents reflux
and redirects blood and embolic flow, coils are not needed in these
procedures. In addition, the new 150 cm length allows us to perform
prostate arterial embolization using a transradial approach."

The United Kingdom's National Institute for Health and Care Excellence
(NICE) recently issued support of prostate artery embolization (PAE) for
the treatment of patients with benign prostatic hyperplasia. With its
ability to eliminate reflux and redirect blood flow away from
surrounding organs, Sniper has the potential to become the device of
choice for PAE procedures.

About Embolx, Inc.

Based in Silicon Valley, Embolx is an emerging commercial-stage medical
device company developing microcatheters for arterial embolization
procedures. Embolx is committed to dramatically improving the treatment
of a variety of conditions, including cancerous tumors, benign prostatic
hyperplasia and uterine fibroids. The Sniper® Balloon Occlusion
Microcatheter sets a new standard for precise embolic delivery and
superior target filling by controlling pressure to direct blood flow
while protecting non-target surrounding tissues. For more information,
please visit www.embolx.com.

View Comments and Join the Discussion!